For the quarter ending 2026-03-31, NKTR has $763,271K in assets. $187,055K in debts. $149,578K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 149,578 | 15,116 | 41,032 | 42,988 |
| Short-term investments | 419,026 | 230,636 | 229,176 | 132,915 |
| Other current assets (including 432 and 429 as of march 31, 2026 and december 31, 2025, respectively, from a related party) | 20,437 | 20,514 | 11,149 | 10,663 |
| Total current assets | 589,041 | 266,266 | 281,357 | 186,566 |
| Property, plant and equipment, net | - | 2,060 | 2,826 | 2,988 |
| Operating lease right-of-use assets | - | 2,941 | 7,171 | 7,585 |
| Equity method investment in gannet biochem | - | 3,491 | 4,837 | 5,371 |
| Long-term investments | 162,993 | 0 | 0 | 0 |
| Other assets | 11,237 | 5,648 | 5,156 | 5,024 |
| Total assets | 763,271 | 280,406 | 301,347 | 207,534 |
| Accounts payable (including 504 and 137 as of march 31, 2026 and december 31, 2025, respectively, to a related party) | 10,026 | 10,770 | 15,563 | 14,281 |
| Accrued expenses (including 1,148 and 994 as of march 31, 2026 and december 31, 2025, respectively, to a related party) | 25,151 | 22,271 | 28,594 | 35,099 |
| Operating lease liabilities, current portion | 22,531 | 20,495 | 22,183 | 22,011 |
| Total current liabilities | 57,708 | 53,536 | 66,340 | 71,391 |
| Operating lease liabilities, less current portion | 60,631 | 65,256 | 69,732 | 74,145 |
| Liabilities related to the sales of future royalties ending balance | - | 63,971 | - | - |
| Less unamortized transaction costs | - | 814 | - | - |
| Liabilities related to the sales of future royalties, net | 60,270 | 63,157 | 75,164 | 80,573 |
| Other long-term liabilities | 8,446 | 8,625 | 5,025 | 5,636 |
| Total liabilities | 187,055 | 190,574 | 216,261 | 231,745 |
| Common stock, 0.0001 par value 390,000,000 shares authorized 29,472,092 shares and 20,378,832 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 3 | 2 | 2 | 1 |
| Capital in excess of par value | 4,382,437 | 3,850,099 | 3,809,235 | 3,667,487 |
| Treasury stock, at cost 0 shares and 552,307 shares as of september 30, 2025 and december 31, 2024, respectively | - | - | 0 | 3,000 |
| Accumulated other comprehensive income (loss) | -1,034 | 17 | 56 | -14 |
| Accumulated deficit | -3,805,190 | -3,760,286 | -3,724,207 | -3,688,685 |
| Total stockholders' equity | 576,216 | 89,832 | 85,086 | -24,211 |
| Total liabilities and stockholders' equity | 763,271 | 280,406 | 301,347 | 207,534 |
NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS (NKTR)